I have been following the progress of Avedro since I first learned about the formation of the company back in May 2009. Now the company has announced completion of the one-year follow up visits of patients enrolled in its two multi-center Phase III clinical studies, although, not releasing the data as yet, which is undergoing timely analysis. When the analysis is completed, I will bring you the results.

Full Story →